Özdirik, B.; Stueven, A.; Knorr, J.; Geisler, L.; Mohr, R.; Demir, M.; Hellberg, T.; Loosen, S.H.; Benz, F.; Wiedenmann, B.;
et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. J. Clin. Med. 2020, 9, 1647.
https://doi.org/10.3390/jcm9061647
AMA Style
Özdirik B, Stueven A, Knorr J, Geisler L, Mohr R, Demir M, Hellberg T, Loosen SH, Benz F, Wiedenmann B,
et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. Journal of Clinical Medicine. 2020; 9(6):1647.
https://doi.org/10.3390/jcm9061647
Chicago/Turabian Style
Özdirik, Burcin, Anna Stueven, Jana Knorr, Lukas Geisler, Raphael Mohr, Münevver Demir, Teresa Hellberg, Sven H. Loosen, Fabian Benz, Bertram Wiedenmann,
and et al. 2020. "Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies" Journal of Clinical Medicine 9, no. 6: 1647.
https://doi.org/10.3390/jcm9061647
APA Style
Özdirik, B., Stueven, A., Knorr, J., Geisler, L., Mohr, R., Demir, M., Hellberg, T., Loosen, S. H., Benz, F., Wiedenmann, B., Tacke, F., Wree, A., Jann, H., & Roderburg, C.
(2020). Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. Journal of Clinical Medicine, 9(6), 1647.
https://doi.org/10.3390/jcm9061647